{
  "docId": "019de073-a711-71bb-a4fc-67d28d18b8d8",
  "docSlug": "26ea3d305f04fe3e604b448e70b259ea",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 46 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 46,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes a breakdown of UC patient severity segments (64%, 31%, 5%).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a711-71bb-a4fc-67d28d18b8d8/21",
  "deckHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8",
  "deckJsonHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8.json",
  "deckAnchorHref": "/decks/019de073-a711-71bb-a4fc-67d28d18b8d8#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.41,
        "x": 0.54,
        "y": 0.16
      },
      "kind": "callout",
      "text": "BEN-8744: Oral, peripherally-restricted, PDE10 inhibitor under development as a first-in-class treatment for refractory UC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3000df74-0e9e-4b2a-b1ee-e57dfa82d577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.43,
        "x": 0.06,
        "y": 0.645
      },
      "kind": "diagram",
      "text": "Ulcerative Colitis breakdown: 64% Mild-moderate, 31% Moderate-severe, 5% Severe-fulminant",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3103426-1f14-4913-96be-7b2dff323cc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.39,
        "x": 0.55,
        "y": 0.31
      },
      "kind": "list",
      "text": "Phosphodiesterase 10 (PDE10) was identified by our TargetID platform as an entirely novel target for the treatment of UC/IBD. Using our Molecular Design expertise we optimally designed a best in class peripherally restricted PDE10 inhibitor: BEN-8744.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fb47dff-7a58-4324-8c17-ed6ef2f176fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "A chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum. Efficacy - 20-40% of Moderate-severe patients do not respond to anti-TNF. Safety - Treatments have many side effects.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ab364b2-718b-4d04-994f-691a81078e92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.39,
        "x": 0.55,
        "y": 0.56
      },
      "kind": "list",
      "text": "BEN-8744 is expected to provide an efficacious disease modifying oral treatment for UC/IBD. BEN-8744 will target Moderate and Severe UC/IBD patients, meeting the unmet need left by existing therapies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6effd0b8-d96a-496b-91e2-c066a56e2b3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Affects 0.4% US population(1), 1.7 million patients in 7MM(1), forecast $7.8bn market by 2026(2)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66bf21ac-55b0-496f-bca4-5d0f3803f19e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.98,
        "x": 0.01,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Sources: (1) GlobalData: Ulcerative Colitis, Global Drug Forecast and Market Analysis to 2026; (2) Evaluate Pharma: Gastro-intestinal, Inflammatory bowel disease (IBD), Ulcerative colitis, Worldwide Overview (report 17th Sep 2021); (3) Roda et al. Clin Transl Gastroenterol 2016; (4) Kobayashi et al Nat Rev Dis Primers 2020 and US FDA Drug Safety Communication 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7507324e-90cb-4e67-bf75-432a47513b91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "BEN-8744 - Ulcerative Colitis (UC)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8279d994-a81f-4f21-aa16-65b6d5454a7c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}